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a b s t r a c t
Activation of spinal cord microglia and astrocytes is a common phenomenon in nerve injury pain models
and is thought to exacerbate pain perception. Following a nerve injury, a transient increase in the presence
of microglia takes place while the increased numbers of astrocytes stay elevated for an extended period of
time. It has been proposed that activated microglia are crucial for the development of neuropathic pain
and that they lead to activation of astrocytes which then play a role in maintaining the long term patho-
logical pain sensation. In the present report, we examined the time course of spinal cord glial activation in
three differentmurine painmodels to investigate if microglial activation is a general prerequisite for astro-
cyte activation in painmodels. We found that two different types of cancer induced pain resulted in severe
spinal astrogliosis without activation of microglia. In contrast, sciatic nerve injury led to a transient acti-
vation of microglia and sustained astrogliosis. These results show that development of hypersensitivity
and astrocyte activation in pain models can take place independent of microglial activation.
 2008 European Federation of Chapters of the International Association for the Study of Pain. Published
by Elsevier Ltd. All rights reserved.
1. Introduction
Nerve injury or inﬂammation may lead to spontaneously
evoked pain and hypersensitivity towards thermal or tactile stim-
uli (Baron, 2006). Pathological pain is associated with altered gene
expression in both primary afferent neurons and second order
spinal cord neurons (Ji et al., 2003; Lee et al., 2005). Furthermore,
microglial activation, a hallmark of CNS pathologies involving neu-
ronal damage or death, also occurs following injury to peripheral
nerves. In the latter scenario, microglia are activated in spinal cord
areas containing the ﬁbers and cell bodies of the damaged nerve
(Hald and Lotharius, 2005; Lin et al., 2007; Sweitzer et al., 1999).
As inhibition of microglial activation blocks hypersensitivity fol-
lowing nerve injury and that intrathecal injection of activated
microglia leads to hypersensitivity, microglia are thought to play
a crucial role in neuropathic pain development (Hains and Wax-
man, 2006; Raghavendra et al., 2003; Coull et al., 2005). Microglial
mediated sensitization may be induced through the release of
nerve sensitizing factors such as brain derived neurotrophic factor,
interleukin (IL)-1b, tumor necrosis factor (TNF)-a, nitric oxide (NO)
and prostaglandins (Coull et al., 2005; Lin et al., 2007; Lund et al.,
2006; Park et al., 2007; Raghavendra et al., 2003). Besides the pro-
algesic effect of microglial released substances, some of these sub-
stances are also capable of activating surrounding astrocytes that
may result in the spinal astrogliosis found to correlate with hyper-
sensitivity in neuropathic rats (Falsig et al., 2004; Raghavendra
et al., 2003; Garrison et al., 1991). Activated astrocytes are specu-
lated to enforce pain sensation through the expression of proalge-
sic cytokines and production of interglial communication networks
(Hansson, 2006).
Stimulation of astrocyte cultures with neurotransmitters, re-
leased by primary afferent neurons, such as glutamate, substance
P (SP), calcitonin gene related peptide (CGRP), ATP and NO induce
astrocyte alterations mimicking those observed in animal pain
models, including increased glial ﬁbrillary acidic protein (GFAP)
expression and changed morphology (Brahmachari et al., 2006; La-
zar et al., 1991; Neary et al., 1994; Noble et al., 1992; Guo et al.,
2007). Thus, besides the putative effect of activated microglia on
adjacent astrocytes, the astrogliosis observed in pain models could
also result from stimulation by neurotransmitters released from
signaling nociceptors. This notion is supported by in vivo studies
showing that the glutamate antagonist MK-801 abrogate pain in-
duced astrogliosis, which emphasizes the role of astrocyte ex-
pressed glutamate receptors or interneuronal synaptic
transmission, for astrocyte activation (Garrison et al., 1994).
In the present study, we investigated the temporal development
of pain behavior and glial activation in two cancer pain models and
a nerve injury pain model. All three models exhibited hypersensi-
tivity and increased spinal GFAP expression while increased pres-
ence of microglia was restricted to the nerve injury model.
Furthermore, GFAP expression along the spinal cord was analyzed
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and astrogliosis was found to span several segments both rostrally
and caudally from the segments where the involved primary affer-
ent neurons entered the spinal cord. These results demonstrate
that activation of astrocytes in pain models can take place indepen-
dent of microglial activation.
2. Materials and methods
2.1. Animals
All experiments were carried out on 6 week old C3H/HeN mice
(M-B Taconic, Tornbjerg, DK). Animals were kept in a room with a
12 h light/dark cycle and were fed standard laboratory diet and tap
water ad libitum. The experiments were approved by the Danish
Committee for Experiments on Animals and conducted according
to the guidelines of the International Association for the Study of
Pain.
2.2. Cell line
NCTC-2472 (NCTC) cells obtained from the American Type Cul-
ture Collection (ATCC, CCL-11) were grown according to ATCC
guidelines. Cultures were harvested when they were 80% conﬂuent
by exposure to calcium free PBS + 1 mM EDTA for 3 min and resus-
pended in a-MEM (Gibco, 22571-020) to a ﬁnal concentration of
either 10  106 or 50  106 cells/ml. Cells were kept on ice until
use.
2.3. Surgeries
Animals were divided into three groups which underwent
either a partial sciatic nerve ligation (PSNL) operation, an injection
of NCTC cells into the right femoral bone marrow cavity or an
injection of NCTC cells in close proximity of the sciatic nerve in
the gluteal region. Two extra groups for investigation of astrogliot-
ic spread were operated. One of these underwent bone cancer
induction and the other a bone cancer sham operation.
PSNL was performed according to Malmberg and Basbaum
(1998). Following anesthesia with Zoletil mix-50 (zolazepam
25 mg/ml, tiletamin 25 mg/ml, xylazin 20 mg/ml, butorphanol
10 mg/ml, KVL, Denmark), 2 ll/g body weight, the sciatic nerve
was exposed through an incision on the back of the mice and
approximately 1/2 of the nerve was tightly ligated with a 8–0 su-
ture. The wound was closed by suturation.
Bone cancer bearing (BCB) mice were produced as previously
described by Schwei et al. (1999) with some modiﬁcations. Brieﬂy,
mice were anesthetized with Zoletil mix-50, 2 ll/g body weight,
and a small incision was made above the right knee. The patella lig-
aments were loosened from the surrounding tissue and the patella
was gently pushed lateral to expose the femoral bone. A small hole
projecting to the marrow cavity was drilled with a 30 gauge needle
between the condyles and 100,000 NCTC cells in 10 ll a-MEM
were injected. The hole was blocked with bone wax (Johnson &
Johnson Intl, W810) and the area was thoroughly cleaned with sal-
ine and a cotton stick and the skin was ligated with wound clips
(Appose 888 6803712, Autosuture, USA). Similar sham operations
were performed with injection of a-MEM only.
Sciatic nerve proximal cancer (SNPC) was induced by injecting
100,000 NCTC cells in 2 ll a-MEM in the gluteal region using a
method described by Shimoyama et al. (2005). Brieﬂy, mice were
anaesthetized with Zoletil mix-50, 2 ll/g body weight and the sci-
atic nerve was exposed through an incision on the lower back of
the animal. Cells were injected in close vicinity of the sciatic nerve
at the level of the trochanter and the wound was closed by
suturation.
2.4. Behavioral tests
Each of the three operated groups was divided into three sub-
groups. Each subgroup was tested at distinct day(s) after which
they were euthanized and prepared for histology. Groups consist-
ing of BCB mice were tested once either on day 7, 14 or 17. SNPC
groups were tested on either day 7 or 14, or on day 17 and 21. PSNL
groups were tested on either day 7, 14 or 21. Before operations,
pretests were performed on a mixed group of 10 mice belonging
to different groups. The mice used for analysis of astrogliotic
spread were tested every other day following day 14 and prepared
for immunohistochemistry when reaching a limb use score of one
or below (see next paragraph).
The animals’ ability to use the affected leg was evaluated in
open ﬁeld limb use tests and tactile hypersensitivity was evaluated
by von Frey monoﬁlaments. In the limb use test, the animals were
allowed to adapt for 10 min in a transparent empty animal cage
(42.5  26.6 cm) after which the use of their right hind limb was
observed for a 3 min period and graded on a continuous and linear
scale from 0 to 4, where 0 designate no use of the affected limb and
4 normal use of limb.
Von Frey tests were performed with monoﬁlaments supplying
pressure from 0.008 to 2 g (North Coast Medical Inc., Morgan Hill,
Ca, USA). The animals were allowed to acclimatize for 1 h before
the test was performed. The mice were stimulated ﬁve times with
each monoﬁlament and three or more paw withdrawals were con-
sidered a positive response. The left paw functioned as an internal
control for each mouse and a withdrawal threshold ratio, deﬁned
as the right paw withdrawal threshold divided by the left paw
withdrawal threshold, was calculated for each mouse and
presented.
2.5. Tissue preparation
Following behavioral tests, mice were processed for
immunohistochemistry. Groups tested on day 7 were euthanized
on day 8. Groups tested on day 14 were euthanized day 14. BCB
mice tested on day 17 were euthanized on day 17. SNPC and PSNL
mice tested on day 17 or 21 were euthanized on day 21. Six naı¨ve
mice, nine weeks old, were also processed for immuno-
histochemistry.
Under anesthesia with Zoletil mix-50, 2 ll/g body weight, the
mice were ﬁxated by perfusion with 15 ml PBS followed by
40 ml 4% paraformaldehyde (PFA), 7 ml/min (Bie & Berntsen).
Spinal cords (segment L4-L6 from PSNL and SNPC mice; L1-L3 or
T1-C3 from BCB mice) were isolated, post ﬁxed in 4% PFA over
night, cryoprotected overnight in 30% sucrose and fast frozen in
OCT compound on a bath of ethanol and dry ice. Bones were iso-
lated from BCB mice, post ﬁxed overnight in 4% PFA and stored
in PBS + 0.1% PFA + 0.1% NaN3 until micro computed tomography
(lCT) scannings had been performed.
2.6. Micro-CT
To quantify bone volume fraction (BV/TV), the right distal femur
from each BCB mouse was scanned with a high resolution lCT sys-
tem (vivaCT 40, Scanco Medical AG., Bassersdorf, Switzerland). The
scanning resulted in three-dimensional (3D) reconstruction of
cubic voxel sizes 25  25  25 lm3, and each 3D image dataset
consisted of approximately 210 lCT slide images. 100 slice images
(2500 lm) were used for the analysis of subchondral bone tissues
(1024  1024 pixels) with 16-bit-gray-levels. BV/TV was computed
based on the bone voxel size and the total number of segmented
voxels in the 3D image, i.e. bone voxel per total specimen voxel
(Ding et al., 1999).
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2.7. Immunohistochemistry
Spinal cords were cut at 30 lm on a cryomicrotome and stained
as free ﬂoating sections. Brieﬂy, sections were collected in
PBS + 0.1% Triton X-100 PBS (TPBS) and OCT compound was re-
moved by thorough washing with TPBS followed by incubation
for 1 h in TPBS at room temperature (RT). For SP, Iba-1 and GFAP
stainings, sections were blocked in BSA/TPBS for 2 h at RT and then
incubated overnight in primary antibodies at 4 C. The following
primary antibodies were used: rabbit anti SP (Chemicon AB1566
1:500 in 0.3% BSA/TPBS), rabbit anti Iba-1 (Wako 019-19741
1:1000 in 1% BSA/TPBS) and rabbit anti GFAP (Dako Z0334 1:500
in 2% BSA/TPBS). Next, sections were washed 3  5 min in TPBS
and incubated in ﬂuorescein isothiocyanate (FITC)-conjugated anti
rabbit IgG (Santa Cruz SC-9020) or Alexa 594 anti rabbit IgG (Invit-
rogen, A31632, 1:300 in BSA/TPBS) for 2 h at RT. Finally, the sec-
tions were washed 3  5 min in TPBS and mounted on precoated
slides (Menzel-Glaser, SuperFrost plus) with permaﬂuor (Thermo,
434990). Stained sections were evaluated with a Zeiss Axioskop
2. The number of Iba-1 positive cells, in spinal cord lamina 1–3
was manually counted. GFAP staining intensity was scored on a
continuous and linear scale from 0 to 4 by a trained and blinded
observer. At least 10 sections from each mouse were used. SP stain-
ing intensity was measured using Image J freeware (National Insti-
tute of Health, USA) on 8 bit grey scale pictures obtained with a
Hamamatsu C4742 CCD camera using a 10  Achromat objective
and a Zeiss Axioskop 2. The area of SP immunostaining and the
mean staining intensity following background correction of the
superﬁcial dorsal horn were measured. Integraded staining values
deﬁned as area in mm2 mean intensity are presented. Presented
pictures were captured with either a Zeiss Axioskop 2 combined
with a Hamamatsu C4742 CCD camera and a 10  Achromat objec-
tive or with a Nikon Eclipse E100M coupled to a Nikon Photo Head
V-TP using a Nikon PanFluor 4  objective. For OX-42 staining, sec-
tions were blocked in 4% donkey serum for 2 h and incubated in rat
anti OX-42 (Bioscience, 14-0112-85, 1:100 in 4% donkey serum
TPBS) over night. Next, the sections were washed 3  5 min in
TPBS and incubated 1 h in biotin coupled goat anti rat (DakoCyto-
mation, E0468), washed 3  5 min in TPBS and incubated 1 h in
HRP coupled streptavidin (DakoCytomation, K3954). Sections were
washed 3  5 min and exposed to NovaRED (Vektor, SK-4800) for
10 min and washed in normal water. Sections were mounted with
Pertex and pictures captured using an Olympus B  51 microscope
and VisioPharm superimage software. At least 3 mice from each
group and time point were analysed. A minimum of 10 sections
from each mouse were used.
2.8. Statistics
All data were analyzed with one-way ANOVA and Newman
Keuls post tests. P < 0.05 were set as the threshold of signiﬁcance.
All data are presented as means ± SEM. For behavioral data, all ani-
mal groups were compared to the pretest group. For staining data,
all groups were compared to tissues originating from naı¨ve mice,
except for SP staining analyses where the side ipsilateral to surgery
was compared to the contralateral side.
3. Results
3.1. Behavioral tests
Following surgeries, animal pain behavior was evaluated for up
to 21 days. To make sure that cancer growth in BCB mice would
not result in fractures or penetrate the bone and spread to the
surrounding muscle tissue, BCB mice were euthanized on
day 17.
At day 7 post surgery, BCB mice expressed tactile hypersensitiv-
ity which was augmented on day 14 and 17. These mice also ex-
pressed a decrease in limb use over time that was found to be
signiﬁcant at day 14 and 17 (Fig. 1b). In contrast, SNPC mice did
not express tactile hypersensitivity at day 7 but had developed tac-
tile hypersensitivity at day 14. However, from day 14 to day 21
these mice seemed to loose sensitivity and also developed
foot-drop which is a sign of compromised nerve function
(Fig. 1a). A decrease in limb use over time was also observed but
not to the extend seen in the BCB mice (Fig. 1b). As previously re-
ported, PSNL mice were hypersensitive to tactile stimuli on all test
days (7, 14 and 21 post surgery). However, the hypersensitivity
never reached the levels observed in the two cancer pain models
(Fig. 1a). As PSNL operations involve direct damage of the motor
neurons projecting to the leg, limb use tests of these animals were
not performed.
3.2. Bone destruction
The extend of tumor induced bone destruction of the distal fem-
oral bone of BCB mice was assessed by lCT scanning. Bone cancer
growth led to a progressive loss of bone tissue and at day 17 the
BV/TV index of the distal femoral bone was decreased to 36%
(Fig. 2). However, at this point there were no visible signs of tumor
growth outside of the bones. The degree of bone destruction
was found to correlate with tactile hypersensitivity (r = 0.73,
p < 0.001) and to decreased limb use (r = 0.71, p < 0.001).
Fig. 1. Pain behavior of BCB, SNPC and PSNL mice. (a) Tactile sensitivity of BCB, SNPC and PSNL mice compared to naı¨ve mice. BCB mice expressed tactile hypersensitivity
determined by von Frey tests on all test days. SNPC mice expressed tactile hypersensitivity at day 14 but at later time points a progressive loss of planter sensation was
evident. PSNL mice expressed tactile hypersensitivity from day 7 to 21. (b) Voluntary limb use of BCB, SNPC and PSNL mice compared with naı¨ve mice. For BCB mice, a
decrease in limb use became signiﬁcant at day 14 post surgery. The SNPC mice also expressed a steady decline in limb use over time. Data represents mean ± SEM. Compared
to naı¨ve mice *, p < 0.05; **, p < 0.01; ***, p < 0.001. Data was analyzed with one way ANOVA with a Newman Keuls post test. For naı¨ve, BCB, SNPC and PSNL mice each time
point represents at least 10, 8, 10 and 6 mice, respectively.
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3.3. Spinal SP levels
One hallmark of injured sensory nerves is decreased levels of
spinal SP at distinct time points following the injury. Spinal SP lev-
els were investigated in the PSNL mice and found to be decreased
at day 7 ipsilateral to the operation side when compared to the
contralateral side. A further decrease was observed at day 14. How-
ever, at day 21, SP levels seemed to approach basal levels again.
During this timecourse, no variations were found in the contralat-
eral side (Fig. 3a and b). These ﬁndings corroborates previous re-
ports on spinal SP expression in this model (Inoue et al., 2006;
Malmberg and Basbaum, 1998).
3.4. Temporal changes in spinal glia activity
Activation of spinal cord microglia in the three different pain
models was investigated by Iba-1 and conﬁrmed by OX-42 immu-
nohistochemistry. PSNL mice showed substantial microglial activa-
tion (Fig. 4a), deﬁned as an increase in number and transition into a
more rounded morphology, in the superﬁcial dorsal horn as well as
lateral in lamina 9. Besides, the whole ipsilateral side of the spinal
cord exhibited a subtle increase in the number and staining inten-
sity of Iba-1 positive microglia. At day 21 the number of microglia,
in PSNL mice, was reduced to baseline levels (Fig. 4a). No effect on
microglial numbers or morphology were observed in the BCB and
SNPC mice at any time point (Fig. 4a).
Similar observations were found when staining for the microg-
lial antigen OX-42 (Fig. 5). PSNL mice expressed abundant OX-42
staining ipsilateral compared to contralateral to the injured nerve,
both in the dorsal and ventral horn, 8 days post surgery. In contrast
BCB mice showed no signs of microglial activation at any time
point. However, 8 days post surgery, a very subtle increase in
OX-42 staining restricted to the lateral superﬁcial dorsal horn
and to the superﬁcial ventral horn was observed SNPC mice. This
increase was not evident at day 14 post surgery.
Activation of spinal cord astrocytes was investigated by GFAP
immunohistochemistry. In BCB mice, GFAP staining intensity in-
creased at day 8 and it continued to increase over time until day
17, where the entire ipsilateral side expressed an immense pres-
ence of GFAP positive cells (Fig. 6). As sham operated mice, in this
model, have been reported to express increased levels of spinal
GFAP (Sevcik et al., 2004), we investigated the degree of GFAP
staining in sham operated mice at the end of the time course.
Fig. 2. Progressive bone loss in BCB mice over time. Bone volume fractions were
determined by lCT and found to decrease compared to naı¨ve mice already 7 days
post cancer inoculation. Bone volume fraction of the distal femoral bone further
decreased over time to reach values of 35% of naı¨ve mice on day 17. Data represents
mean ± SEM. Compared to pretest values *, p < 0.05; **, p < 0.01; ***, p < 0.001. Data
was analyzed with one way ANOVA with a Newman Keuls post test. n = 5, 5, 4, 4 for
pretest, day 7, 14 and 17, respectively.
Fig. 3. Decreased spinal SP levels in PSNL mice. (a) Staining intensity of spinal SP in PSNL mice showed that SP levels had decreased in response to nerve injury
(representative staining at day 14 post injury). (b) Whole superﬁcial dorsal horn staining intensity was measured after background correction. No difference in SP levels
contralateral to the nerve injury was observed at any time point. Ipsilateral to the injury, a transient and signiﬁcant decrease was seen. Data represents mean ± SEM. *,
p < 0.05; **, p < 0.01. Data was analyzed with one way ANOVA with a Newman Keuls post test. n = 4, 4, 3 for day 7, 14 and 21, respectively. Scale bar = 100 lm.
Fig. 4. Number of Iba-1 positive cells with glial morphology and GFAP staining intensity. (a) Spinal cords were stained with Iba-1 antibodies and the number of stained cells
were determined ipsilateral to the surgery. PSNL mice expressed an increased presence of microglia, while BCB mice and SNPC mice did not show any alterations. (b) GFAP
staining intensity was evaluated ipsilateral to the surgery and scored on a scale from 0 to 4. All three models developed astrogliosis over time but to various degrees. Data
represents mean ± SEM. Compared to naı¨ve mice ***, p < 0.001. Data was analyzed with one way ANOVA with a Newman Keuls post test. For naı¨ve, BCB, SNPC and PSNL mice
each time point represents at least 6, 4, 4, 4, mice respectively.
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We found that the GFAP staining intensity in sham operated mice
was increased compared to naı¨ve mice but not to the extend found
in the BCB mice (data not shown).
SNPC mice expressed a small increase in GFAP staining at day 8
and 14 which was markedly increased at day 21 (Fig. 4b).
PSNL mice expressed increased GFAP staining, which remained
constant at all time points examined (Fig. 4b). In the PSNL mice,
astrogliosis was most pronounced in areas, which also displayed
an increased presence of microglia (Fig. 7).
As SNPC and PSNL sham operated mice do not express any in-
crease in spinal GFAP levels (Coyle, 1998) (personal observations),
we did not include these groups in the present study.
3.5. Spread of spinal astrogliosis
Spinal cords derived from BCB mice were divided according to
vertebrae entities from T1 to S1 and stained for GFAP. Increased
astrogliosis ipsilateral to the cancer bearing limb was observed in
spinal cord segments T10–S1. The central part of this segment
(T12–L5) showed the most extensive astrogliosis, whereas the
astrogliosis decreased in the distal parts until it reached levels sim-
ilar to that observed in the contralateral side (Fig. 8). No spread of
astrogliosis was found in sham operated mice.
4. Discussion
In the present report, we have demonstrated that in pain mod-
els astrocyte activation can take place independent of microglial
activity, though microglial activation may also lead to secondary
astrogliosis in nerve injury pain models. The spread of astrogliosis
was examined in BCB mice and astrogliosis was shown to be pres-
ent in spinal cord segments adjacent to the segments, where the
primary afferent neurons innervating the femoral bone, enters
the spinal cord.
Spinal cord astrogliosis is a hallmark of chronic pain models,
including classical neuropathic and inﬂammatory models such as
PSNL, spinal nerve ligation, sciatic nerve transection, bone cancer
pain as well as complete Freund’s adjuvant (CFA), formalin and
zymosan injection (Colburn et al., 1999; Honore et al., 2000; Med-
hurst et al., 2002; Raghavendra et al., 2004; Sweitzer et al., 1999)
which indicates that spinal astrogliosis is inevitable following an
insult that leads to sustained nociceptive signaling to the CNS
Fig. 5. Spinal expression of OX-42. Spinal cord sections obtained 8 days post surgery and stained with antibodies against the microglial marker OX-42 are presented. Pictures
were captured using the Olympus BX51 microscope and VisioPharm superimage software. Arrows indicate areas with increased OX-42 staining. Scale bar = 200 lm.
Fig. 6. Widespread spinal astrogliosis in BCB mice. Immunohistochemical staining of spinal GFAP reveals massive astrogliosis in all spinal cord lamina of BCB mice 17 days
post surgery. High resolution pictures were constructed by multiple 8 bit picture fragments obtained with the Zeiss Axioskop 2, Hamamatsu C4742 CCD camera and a
10  Achromat objective. Scale bar = 200 lm.
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and could be expected to be found in other models involving high
and persistent sensory activity.
Von Frey tests of SNPC mice, showing ﬁrst an increase (day 14)
and thereafter a decrease in tactile hypersensitivity is in agreement
with data presented by Shimoyama et al. (2005), where both tactile
and thermal sensitivity was lacking 18 days post cancer inocula-
tion. In spite of the lost sensitivity they showed that SNPCmice still
experienced pain by use of ﬂinch tests and spinal upregulation of
Fos, a marker of neuronal activity (Coggeshall, 2005; Shimoyama
et al., 2005). The loss of sensation following a period of hypersen-
sitivity in these mice is likely accounted for by compression of the
sciatic nerve by the growing tumor. This would also explain the
foot-drop tendency, a symptom observed in humans with compro-
mised function of the sciatic nerve.
The ﬁndings that astrogliosis in the BCB and SNPC mice occurs
independent of microglial activation suggest that astrocytes are
activated as a direct consequence of neuronal activity. This would
also explain why inﬂammatory pain in rats could lead to a 300%
GFAP upregulation already after 30 min (Guo et al., 2007). A link
between neuronal activity and GFAP expression is supported by
the ﬁndings that electrical induced seizures lead to increased GFAP
gene transcription not only in the directly affected brain areas but
also in synaptically associated brain areas (Steward et al., 1991).
Furthermore, in an inﬂammatory pain model, astrogliosis has been
shown to be abrogated by a nerve blockade with lidocaine thereby
emphasizing the importance of neuronal signal transduction for
astrocyte activation (Guo et al., 2007). Though several nerve de-
rived factors such as glutamate, SP, CGRP, NO and ATP have the po-
tential to activate astrocytes in vitro, their contribution in
astrocyte activation in vivo is still unresolved. Besides neurotrans-
mitters, other factors, such as potassium released from ﬁring neu-
rons have the potential to activate astrocytes. Furthermore,
cytokines released from tumors might indirectly sensitize the
spinal cord astrocytes (Hansson, 2006).
Sensitivity tests of the affected nerves in the two cancer pain
models are hampered by the model design. In the case of SNPC
mice, the present study shows, that sciatic nerve compression by
the tumor results in loss of sensitivity after a period with plantar
hypersensitivity. However, spinal Fos staining shows that SNPC
mice still experience chronic nociceptive signaling regardless of
the loss of plantar sensitivity (Shimoyama et al., 2005). In BCB mice
the direct affected nerve proves difﬁcult to test by application of
stimuli to the skin. However, in these two cancer pain models,
where astrocytes are likely activated through neuronal activity
and not by activated microglia, GFAP could possibly be used as a
neurochemical marker of nociception.
The ﬁndings that astrogliosis was restricted to areas with in-
creased microglial activity in some of the PSNL mice, suggest a con-
nection between these two phenomena in this model. Though the
exact nature of microglial derived astrocyte activators, in regard to
pain pathology, remains unknown, combinations of transmitters,
which can be released by activated microglia, such as TNF-a, IL-
1b and NO have been shown, in related research ﬁelds, to stimulate
astrocyte activation (Brahmachari et al., 2006; Falsig et al., 2004;
Lund et al., 2006).
An interesting phenomenon in BCB mice is the presence of plan-
tar hypersensitivity which reﬂects changes in nociceptive signal
transduction by the sciatic nerve to higher brain centers. How bone
cancer affecting the femoral nerve leads to plantar hypersensitivity
is not yet known but could result from heterosynaptic sensitization
of spinal cord neurons (Ji et al., 2003). However, peripheral mech-
anisms may also be involved as the dorsal root ganglia (DRG) con-
taining the cell bodies of the femoral bone innervating neurons
(L1–L3) also to a limited extend contain neurons which make up
part of the sciatic nerve (Peters et al., 2005). In response to femoral
bone cancer, these DRG express an increased presence of macro-
phages and satellite cells (Peters et al., 2005) which could produce
diffusible substances that could sensitize surrounding neurons
(Hanani, 2005; Ma and Quirion, 2005). The tomographic examina-
tion of BCB mice, presented in this report, showed that astrogliosis
was evident from spinal cord segment T10–S1. The nerves that
innervate the femoral bone enters the spinal cord in segment L1–
L3 (Peters et al., 2005) meaning that astrogliosis had spread into
distant spinal cord segments both caudally and rostrally from that
area. Astrogliotic spread may reﬂect the collateral arborizations of
dorsal root ﬁbers in the spinal cord (Shortland and Wall, 1992) but
it could also result from signal transduction from the site of pri-
mary afferent entrance to adjacent spinal cord segments by inter-
segmental propriospinal neurons (Almeida et al., 2004). The ability
of astrocytes to construct networks, which are capable of transmit-
ting signals for long distances and which result in the secretion of
substances that can induce astrocyte differentiation and prolifera-
tion, could also be involved in generation of astrogliotic spread
(Faijerson et al., 2006; Franke et al., 1999; Haydon, 2001).
As both hypersensitivity related to distinct spinal cord seg-
ments and astrogliosis is found to spread along the spinal cord
Fig. 7. Spinal cord GFAP and Iba-1 staining of PSNL mice. GFAP and Iba-1 staining of spinal cord sections from PSNL mice revealed increased levels of both GFAP and Iba-1
positive cells. Increased numbers of Iba-1 positive cells were most pronounced in the superﬁcial dorsal horn and superﬁcial ventral horn (lamina 9) though the entire side of
the spinal cord ipsilateral to the nerve ligation exhibited a higher staining intensity of the individual Iba-1 positive cell. GFAP staining was, in contrast to BCB and SNPC mice,
restricted to spinal cord areas which also express increased levels of Iba-1 positive cells. The presented sections were derived from PSNL mice 14 days post surgery. Scale
bar = 300 lm.
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these two phenomena may be interrelated. In that case, the spread
of hypersensitivity could be the primary event which, in turn, trig-
gered astrogliosis but the spread of astrogliosis could also lead to
spread of hypersensitivity as astrocytes are known to modulate
neuronal signal transduction (Volterra and Meldolesi, 2005).
In the present report, we have shown that astrogliosis is a com-
mon hallmark in three different pathological pain models and that
it can take place independent of microglial activation thus proving
the presence of discriminative mechanisms behind microglial and
astrocytic activation in pain models. As spinal astrogliosis in the
Fig. 8. Spread of spinal astrogliosis in BCB mice. 6 BCB mice, which had developed signiﬁcant and severe pain behavior (Limb use 61), and 3 sham mice were used to
investigate the spread of spinal astrogliosis. Spinal vertebrates with designations are shown on the left. Nerve roots projecting from the spinal cord to their respective DRG are
shown between the vertebrates and the spinal cord (spinal cord segments T2, L1 and S1 are marked). Just on the right hand side of the spinal cord is the degree of spinal
astrogliosis marked by horizontal ﬁne lines. On the right hand side of the diagram are representative spinal cord GFAP stainings from various spinal cord segments. Scale
bar = 1000 lm.
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cancer pain models may reﬂect the degree of neuronal activity
GFAP could possibly be used as a marker for the duration and
severity of pain in these models. Furthermore, the observed spread
of astrogliosis in BCB mice offers an explanation of how hyperalge-
sia may spread to areas not related to the primary source of pain,
though the opposite situation, where a spread of hypersensitivity
activates astrocytes adjacent to the primarily activated astrocytes,
should not be ruled out. The factors leading to astrocyte activation
in pain models still remain unidentiﬁed, though several nerve de-
rived factors have been proposed. How astrocytes may facilitate
pain transmission has yet to be ﬁnally elucidated.
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